IceCure Medical Ltd (NASDAQ:ICCM) Q2 2024 Earnings Call Transcript August 20, 2024 10:00 AM ET

Company Participants

Michael Polyviou - IR
Shad Good - VP of North American Sales
Ronen Tsimerman - CFO and COO

Conference Call Participants

Anthony Vendetti - Maxim Group
Kemp Dolliver - Brookline Capital Markets
Ben Haynor - Lake Street
Yi Chen - H.C. Wainwright

Operator

Good morning, and thank you for standing by. Currently, all participants are in a listen-only mode. After management's discussion, there will be a question-and-answer session. Please be advised that today's conference will be recorded. I would now like to turn the conference over to Michael Polyviou. Please go ahead.

Michael Polyviou

Thank you, Joni, and welcome to IceCure Medical's conference call to review the financial results as of and for the six months ended June 30, 2024, and provide an update on recent operational highlights. You may refer to the earnings release that we issued earlier this morning. Eyal Shamir, the company's CEO, is traveling and due to a last minute poor communication network in his location, is unable to dial in and participate Therefore, joining today are IceCure Medical's VP of North American Sales, Shad Good; and the company's CFO and COO, Ronen Tsimerman.

Before we begin, I'll now take a moment to read the statement about forward-looking statements. The call and the question-and-answer session that follows that contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements in this presentation when we discuss upcoming regulatory review process by the FDA in its medical device advisory panel, the expected time line for reporting interim analysis of ICESECRET kidney cancer trail, in the pursuit of regulatory approvals in various jurisdictions, including with respect to reimbursement codes for physician expenses and potential demand for a market adoption of IceCure's minimal invasive cryoablation technology, advancing the regulatory marketing and commercial strategies in our belief that we have resources to execute our clinical, regulatory and commercial objectives till the end of 2024 and into 2025. Because such statements yield future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of IceCure could differ materially from those described in or implied by the statements during this call. The forward-looking statements contained or implied during this call are subject to other risks and uncertainties, many of which are beyond the control of the company, including those set forth in the Risk Factors section of the company's annual report on Form 20-F for the year ended December 31, 2023, filed with the SEC on April 3, 2024, which is available on the SEC's website at www.sec.gov. The company disclaims any intention or obligation, except as required by law to update or revise any forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and speaks only as of the live broadcast today, August 20, 2024.